Ninlaro

News

Takeda's Ninlaro fails phase 3 amyloidosis trial

Takeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not meet the first of two primary endpoints.

News

Takeda’s myeloma drug Ninlaro approved in Europe

Takeda has gained European Union approval of its multiple myeloma drug Ninlaro for second line use – joining a wave of new treatments for the incurable condition.

News

Novavax critic Shah Capital ends its activism campaign

Shah Capital has ended attempts to exert influence over vaccine firm Novavax, bringing more than years of pressure on management to an end.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks